PatersonDL, SwindellsS, MohrJet al.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med, 2000; 133:21–30.
2.
Guidelines for the Use of AntiretroviralAgents in HIV-1-Infected Adults Adolescents1–166. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 2011 August 31.
3.
CohenC. Low-level viremia in HIV-1 infection: Consequences and implications for switching to a new regimen. HIV Clin Trials, 2009; 10:116–124.
4.
RaffantiSP, FuscoJS, SherrillBHet al.Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr, 2004; 37:1147–1154.
5.
MurriR, LepriAC, CicconiPet al.Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: Evidence from the Italian cohort of antiretroviral-naive patients study. J Acquir Immune Defic Syndr, 2006; 41:23–30.
6.
TarwaterPM, GallantJE, MellorsJWet al.Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS, 2004; 18:2419–2423.
7.
BrigidoL, RodriguesR, CassebJet al.CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: Partial control of viremia is associated with favorable outcome. AIDS Patient Care STDs, 2004; 18:189–198.
8.
TenorioAR, JiangH, ZhengYet al.Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses, 2009; 25:135–139.
